In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas

Journal of Pathology

Volumn 183, Issue 2, 1997, Pages 182-187

  Xerri, Luc ^a   Devilard, Elisabeth ^a   Hassoun, Jacques ^a   Olive, Daniel ^a   Birg, Françoise ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

CD80; CD86; CTLA4; Hodgkin's disease; Non Hodgkin's lymphoma

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOENZYME TECHNIQUES; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES;

EID: 0030874921     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199710)183:2<182::AID-PATH918>3.0.CO;2-I     Document Type: Article

References (35)

1. Brunet JF, Denizot F, Luciani MF, et al. A new number of immunogiobulin superfamily CTLA4. Nature 1987; 328: 267-270.
2. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321-325.
3. Linsley P, Brady W, Urnes M, Grosmaire LS, Damle NK. Ledbetter JA. CTLA4 is a second receptor for B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
4. Linsley PS, Clark EA, Ledbetter JA. The T cell antigen, CD28, mediates adhesion with B cells by interacting with the activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87: 5031-5039.
5. Azuma M, Ito D, Yagida H, et al. B70 antigen is a second ligand for CTLA4 and CD2K. Nature 1993; 366: 76-79.
6. Engle P, Gribben JG, Freeman GJ, et al. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 1994; 84: 1402-1407.
7. Lanier L, O'Fallon S, Somoza C. et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation. cytokine production, and generation of CTL. J Immunol 1995; 154: 97-105.
8. Linsley P, Greene JL, Tan P, et al. Coexpression and functional cooperation of CTLA4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176: 1595-1604.
9. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. Activated human B lymphocytes expressed three CTLA-4 counter-receptors that costimulate T-cell activation. Proc Sci Acad Sci USA 1993; 90: 11059-11063.
10. Walunas TL, Lenschow DJ, Bakker CY. et al. CTLA4 can function as a negative regulator of T-cell activation. Immunity 1994; 1: 405-413.
11. Gribben JG, Freeman GJ, Boussiotis VA. et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995; 92: 811-815.
12. Linsley PS, Golstein P. Lymphocyte activation: T-cell regulation by CTLA-4. Curr Biol 1996; 6: 398-400.
13. Rudin CM, Van Dongen J, Thompson CB. Apoptotic signalling in Iymphocytes. Curr Opin Hematol 1996; 3: 35-40.
14. Boise LH, Noel PJ, Thompson CB. CD28 and apoptosis. Curr Opin Immunol 1995; 7: 620-625.
15. Radvanyi G, Shi Y, Vaziri H. et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996; 156: 1788-1798.
16. Boise LH, Minn AJ, Noel PJ. et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 1995; 3: 87-98.
17. Tivol EA, Borriello F, Schweizter AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction. revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
18. Waterhouse P, Penninger JM, Timms E. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 1995; 270: 985-988.
19. Plumas J, Chaperot L, Jacob MC. et al. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogenic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of costimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumour cells. Eur J Immunol 1995; 25: 3332-3341.
20. Schultze JL, Cardoso AA, Freeman GJ. et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200-8204.
21. Nowaza Y, Wachi E, Tominaga K, Abe M, Wasaka H. A novel monoclonal antibody (fun-1) identifies an activation antigen in cells of the B-cell lineage and Reed-Sternberg cells. J Pathol 1993; 169: 309-315.
22. Lee Harris N, Jaffe ES, Stein H. et al. A revised Euro-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
23. Xerri L, Carbuccia N, Parc P, Hassoun J, Birg F. Frequent expression of Fas-APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 1995; 104: 424-430.
24. Castan J, Tenner-Racz K, Racz P, Fleischer B, Bröcker BM. Accumulation of CTLA4 expressing T lymphocytes in the germinal centers of human lymphoid tissues. Immunology (in press).
25. Cordell JL, Falini B, Erber WN. et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP) complexes. J Histochem Cytochem 1984; 32: 219-229.
26. Falini B, Abdulaziz Z, Gerdes J. et al. Description of a sequential staining procedure for double immunoenzymatic staining of pairs of antigens using monoclonal antibodies. J Immunol Methods 1986; 93: 265-272.
27. Linsley PS, Bradshaw J, Greene J, Peach R, Bennet KL, Mittler R. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4: 535-543.
28. Hathcock KS, Laszlo G, Pucilo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180: 631-640.
29. Munro JM, Freeman AS, Aster JC. et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793-798.
30. Delabie J, Ceuppen JL, Vandenberghe P, de Boer M, Coorevits L, De Wolf-Peeter C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993; 82: 2845-2852.
31. Delabie J, Chan WC, Weisenburger DD, De Wolf-Peeters C. The antigen-presenting cell function of Reed-Sternberg cells. Leukemia Lymphoma 1995; 18: 35-40.
32. Kuiper HM, Brouwer M, Linsley PS, Van Lier RAW. Activated T cells can induce high levels of CTLA-4 expression on B cells. J Immunol 1995; 155: 1776-1783.
33. Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor. J Immunol 1996; 156: 2909-2917.
34. Xerri L, Mathoulin MP, Birg F, Bouabdallah R, Stoppa AM, Hassoun J. Heterogeneity of rearranged T-cell receptor V-α and V-β transcripts in tumor-infiltrating lymphocytes from Hodgkin's disease and non-Hodgkin's lymphoma. Am J Clin Pathol 1994; 101: 76-80.
35. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1737.